Johnson & Johnson $JNJ Shares Sold by Northstar Group Inc.

Northstar Group Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,923 shares of the company’s stock after selling 692 shares during the period. Johnson & Johnson comprises approximately 1.0% of Northstar Group Inc.’s investment portfolio, making the stock its 24th biggest position. Northstar Group Inc.’s holdings in Johnson & Johnson were worth $6,251,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 1.4%

JNJ stock opened at $188.51 on Friday. The company has a market cap of $453.98 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.37 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The firm has a 50-day moving average of $176.18 and a two-hundred day moving average of $162.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $187.47.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.